Dr. Daniel Howell Verified by iCliniq
MBBS., MSC CLINICAL DRUG DEVELOPMENT
Professional Bio:
Dr. Daniel Howell specializes in Internal Medicine with a special interest in lung conditions such as asthma, COPD, interstitial lung disease, and pulmonary embolism. He attended one of the highest-ra... Read More
Experience
11+ Yrs
Patients
Helped 50 patients
Fee
Query : $49
Phone/Video : $59
Professional Bio
Dr. Daniel Howell specializes in Internal Medicine with a special interest in lung conditions such as asthma, COPD, interstitial lung disease, and pulmonary embolism. He attended one of the highest-ranking medical schools in the UK, Newcastle University, and completed his Master of Science in Clinical Drug Development at University College, London. He completed the Internal Medicine Residency at Albert Einstein College of Medicine, Montefiore in New York City. His research has included anticoagulation, asthma, and COVID-19. He worked in the Intensive Care Unit during the peak of COVID-19 in New York City and has significant experience with managing this disease.
Academics & Trainings
MBBS
Newcastle University
2012
MSC CLINICAL DRUG DEVELOPMENT
University College London
2017
Awards & Publications
Dr. Daniel Howell has written the following: Manuscripts - 1. Mathews KS, Howell D. Risks of removing the default: Lung protective ventilation is for everyone. CHEST Physician. 2019 14(4): 42-43; 2. Howell D, Zaremski L, Fisher J, Ferrick K, DiBiase L, et al. Bleeding Risk with Apixaban when Using Cardiac P-Glycoprotein Inhibitors. Int J Clin Cardiol Res. 2018;2(3): 061-065; 3. Howell D, Galen BT Recurrent rheumatoid pleural effusions complicated by Mycobacterium heckeshornense infection. Respiratory medicine case reports 2018 25 333-335. Abstracts - 1. Andrae M, Mathews KS, Howell D, Zhang Q, Richardson L Patient Preferences for Proactive Consent for Multiple Clinical Trials Society of Critical Care Medicine February 2020; 2. Howell D, Zaremski L, Gross JN, Romero J, Kim S, Di Biase L, Fisher JD, Ferrick K, Krumerman A. Risk With Co-administration Of Commonly Used Cardiac P-glycoprotein Inhibitors And Apixaban. American Heart Association, Toronto November 2017; 3. Colvin MO, Gibson CD, Howell D, Kalininsky A, Lorenzen SJ, Hsieh SJ, Gershengorn H. Effectiveness of early mobilization in reducing the rate of thromboembolic disease among adult medical ICU patient. CHEST, Toronto, October 2017; 4. Amell F, Shetha P, Howell D, Merkin R, LeFrancois D, Elwyn G. Preference Agnosia in Practice Questions for Medical Licensing and Board Examinations. 5th Annual Lown Conference in Boston. (2017) Presentation of abstract won 2nd place; 5. Howell D, Warhit M, Bhargava A and Galen BT. Recurrent Rheumatoid Pleural Effusions Complicated by Mycobacterium heckeshornense Infection. Society of General Internal Medicine annual meeting. Washington DC May 2017. Posters - 1. Howell D., Hoch E., Shulman E., Gross JN, Romero J, Kim S, Di Biase L, Fisher JD, Ferrick K, Krumerman A. Ethan Hoch, Eric Shulman, Luigi Di Biase, Kevin J Ferrick, John Fisher, Andrew Krumerman. Interaction between amiodarone and rivaroxaban and the risk of major bleeding. Heart Rhythm, Vol. 13 No. 5 May Supplement 2016 and published abstract. 2. Christofi G, Chandratheva A, Walters C, Howell D, Simister R The value of medical intervention within an early supported discharge team: a prospective cohort study. European Stroke Journal May 2016, vol 1, issue 1 suppl pg 5281. Poster and published abstract. 3. Howell D, Shaines M Musculoskeletal chest pain: Not just a diagnosis of exclusion. Society of General Internal Medicine May 2016 Howell D, Nelligan L Shortening wait times for transfer to a PCI center for patients with NSTE-ACS. Oxford Foundation Symposium October 2013.